ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

House, Senate Must Resolve Major Differences In Authorization Bills

September 12, 1980

Task Force Members Give Mea Culpa at Congressional Hearing

December 4, 2009

Univ. Of Pittsburg distances Itself From Fisher

June 24, 1994

In Brief: Resolution Seeks Two-Fold Increase For NIH; Hartwell Named President At Fred Hutchinson

January 31, 1997

Conversation With The Cancer Letter: How ASCO’s Guideline Differs—And Why

July 20, 2012

Scripps, Sandoz Deal Becomes Case Study As NI Rethinks Sponsored Research

January 28, 1994